We read with extreme interest the study by Cognat et al 1 investigating the in vivo functionality of the Arg169Cys archetypal mutation in NOTCH3. In particular, they broaden our knowledge on cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mechanism showing that white matter pathology was only found in mice with the CADASIL mutation, despite normal NOTCH3 signaling and, thus, argued against a loss of function as a general driving mechanism for white matter lesions in CADASIL. In addition, they stressed the fact that the loss of NOTCH3 function does not cause CADASIL phenotypic manifestations. As an additional piece of evidence, they quoted the recent report by Rutten et al 2 describing a NOTCH3 nonsense mutation in exon 3 (c.307C>T, p.R103X) in 2 siblings. One of them presented a clinical picture suggestive of CADASIL, the other one was symptom free, with magnetic resonance and skin biopsy findings not typical of CADASIL. Therefore, it was suggested that hypomorphic NOTCH3 mutations do not cause CADASIL. However, significant efforts have been made to clarify whether hypomorphic NOTCH3 mutations are neutral polymorphisms or causative for a distinct cerebrovascular entity, and large consecutive series have strongly been encouraged. 3 In this view, we described the same nonsense mutation in 1 patient with parkinsonism, cognitive impairment, and typical CADASIL neuroimaging features. 4 Moreover, the family history was positive for cerebral ischemic events in at least 2 different generations and the mutation clearly segregates with the disease. Considering that the molecular mechanisms leading to the development of NOTCH3-related diseases remains elusive, 5 it is possible to hypothesize the presence of different mutations underlying phenotype heterogeneity. Therefore, the p.Arg103X nonsense mutation could be responsible of a CADASIL-like syndrome with reduced penetrance and increased clinical heterogeneity and might play a greater role in ischemic stroke than previously thought, with a spectrum of CADASIL-like disorders because of NOTCH3 variants.
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To the Editor:
We read with extreme interest the study by Cognat et al 1 investigating the in vivo functionality of the Arg169Cys archetypal mutation in NOTCH3. In particular, they broaden our knowledge on cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mechanism showing that white matter pathology was only found in mice with the CADASIL mutation, despite normal NOTCH3 signaling and, thus, argued against a loss of function as a general driving mechanism for white matter lesions in CADASIL. In addition, they stressed the fact that the loss of NOTCH3 function does not cause CADASIL phenotypic manifestations. As an additional piece of evidence, they quoted the recent report by Rutten et al 2 describing a NOTCH3 nonsense mutation in exon 3 (c.307C>T, p.R103X) in 2 siblings. One of them presented a clinical picture suggestive of CADASIL, the other one was symptom free, with magnetic resonance and skin biopsy findings not typical of CADASIL. Therefore, it was suggested that hypomorphic NOTCH3 mutations do not cause CADASIL. However, significant efforts have been made to clarify whether hypomorphic NOTCH3 mutations are neutral polymorphisms or causative for a distinct cerebrovascular entity, and large consecutive series have strongly been encouraged. 3 In this view, we described the same nonsense mutation in 1 patient with parkinsonism, cognitive impairment, and typical CADASIL neuroimaging features. 4 Moreover, the family history was positive for cerebral ischemic events in at least 2 different generations and the mutation clearly segregates with the disease. Considering that the molecular mechanisms leading to the development of NOTCH3-related diseases remains elusive, 5 it is possible to hypothesize the presence of different mutations underlying phenotype heterogeneity. Therefore, the p.Arg103X nonsense mutation could be responsible of a CADASIL-like syndrome with reduced penetrance and increased clinical heterogeneity and might play a greater role in ischemic stroke than previously thought, with a spectrum of CADASIL-like disorders because of NOTCH3 variants.
